Clinical Trial Update: A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) [Phase 2]

View source ↗

Summary

Phase 2 long-term extension results for TCH346 vs placebo in patients with Amyotrophic Lateral Sclerosis have been completed. The study sponsor is Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TCH346 (TCH-346)

Snippet

Sponsor: Novartis | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED